Tuesday, January 28, 2025
HomeHealthTrump health care plan likely good for pharmaceutical companies

Trump health care plan likely good for pharmaceutical companies

U.S. President Donald Trump speaks about prescription drug prices during an appearance in the Brady Press Briefing Room at the White House in Washington, U.S., November 20, 2020. Carlos Barria | Reuters
Pharmaceutical companies appear to be hopeful about their growth under a Trump administration, after former President Joe Biden took a hardline stance on the industry for the last four years. Like his predecessor, President Donald Trump will make lowering health-care costs for Americans a priority. It’s a popular bipartisan issue in a nation where patients pay two-to-three times more for prescription drugs than people in other developed countries. Trump has not yet outlined specific health policy plans, but his new administration will likely take a different, more pro-business approach than Biden’s did. Drugmakers hope Trump will focus more on cracking down on middlemen called pharmacy benefit managers, while taking heat off the prices the pharma companies themselves charge, promoting drug innovation and improving patient access to treatments. Those companies are particularly eager to see changes to Biden’s Inflation Reduction Act, which includes landmark provisions that aim to make medicines more affordable — but that the industry views as a threat to innovation and its profits. That was the sentiment during the JPMorgan Health Care Conference in San Francisco this month, the largest gathering in the U.S. of pharma and biotech executives and investors. The annual conference gives a pulse on the industry’s outlook for the year ahead. To no surprise, health policy questions dominated many of the conversations as Trump was heading into office. Trump isn’t exactly a friendly face to the U.S. pharmaceutical industry, as he targeted companies and high drug costs during his first term through proposals like linking government payments for medicines to lower prices paid abroad. Still, executives stressed they are ready to work with Trump, who some described as being willing to hear out their grievances.

web-intern@dakdan.com

RELATED ARTICLES
- Advertisment -

Most Popular

Recent Comments

Translate »
×